Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung

Anticancer Res. 2021 Apr;41(4):1997-2005. doi: 10.21873/anticanres.14967.

Abstract

Background/aim: We aimed to evaluate the clinical outcomes of oligometastatic colorectal cancer in the liver and lung treated with carbon-ion radiotherapy (C-ion RT).

Patients and methods: Nineteen consecutive patients with oligometastatic colorectal cancer in the liver or lung who received C-ion RT were analyzed. The doses of C-ion RT were 60.0 Gy [relative biological effectiveness (RBE)] in 4 fractions, 60.0 Gy (RBE) in 12 fractions, or 64.8 Gy (BRE) in 12 fractions.

Results: The median follow-up duration was 19 months. There were 23 tumors in 19 patients. The 2-year overall survival and local control rates for the whole patient cohort were 100% and 67%, respectively. None of the patients developed grade 2 or higher acute or late toxicities.

Conclusion: C-ion RT for oligometastatic colorectal cancer in liver and lung provides favorable clinical outcomes. These outcomes suggest C-ion RT is a treatment option for oligometastatic colorectal cancer in liver and lung.

Keywords: Carbon-ion radiotherapy; colorectal cancer; liver metastases; lung metastases; oligometastases.

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / radiotherapy*
  • Adenocarcinoma / therapy
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / radiotherapy*
  • Colorectal Neoplasms / therapy
  • Combined Modality Therapy / methods
  • Female
  • Heavy Ion Radiotherapy* / adverse effects
  • Heavy Ion Radiotherapy* / methods
  • Humans
  • Liver Neoplasms / radiotherapy*
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy
  • Lung Neoplasms / radiotherapy*
  • Lung Neoplasms / secondary
  • Lung Neoplasms / therapy
  • Male
  • Middle Aged
  • Radiotherapy, Adjuvant / adverse effects
  • Radiotherapy, Adjuvant / methods
  • Retrospective Studies
  • Treatment Outcome
  • Tumor Burden / radiation effects

Substances

  • Antineoplastic Agents